The immunosuppressive properties of mesenchymal stem cells (MSC) make them particularly attractive to manipulate graftversus-host disease (GVHD). So far, the experience of using MSC to treat GVHD is limited to a few cases, controversial results come from preclinical models and several issues remain to be clarified. The present studies were designed to address these questions in a xenogenic model testing the ability of umbilical cord blood-derived MSC (UCB-MSC) to prevent and/or treat GVHD. Sublethally irradiatiated non-obese diabetic/severe combined immunodeficiency NOD/SCID mice transplanted with human peripheral blood mononuclear cells (huPBMC) showed extensive human T-cell proliferation in the peripheral blood, lymphoid and non-lymphoid tissues, which evolved in extensive GVHD (wasting, ruffled hair and hunched back). The mice treated with a single dose of UCB-MSC did not behave differently form the controls. However, when UCB-MSC were given at weekly intervals, there was a marked decrease in human T-cell proliferation and none of the mice developed GVHD. No therapeutic effect was obtained if UCB-MSC were administered at onset of GVHD. This work supports the clinical use of MSC in stem cell transplantation as a prophylaxis rather than treatment of GVHD.
Introduction
Graft-versus-host disease (GVHD) is the most relevant cause of post-transplant morbidity and mortality after allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions. 1 Response of GVHD to steroids dramatically determines the long-term survival because approximately 80% of patients with steroid-refractory disease die. To date, salvage treatments involve anti-thymocyte globulin 2, 3 or other monoclonal antibodies, 4 ,5 which only induce a transient improvement in less than half of these patients. The figures related to chronic GVHD are not dissimilar. 6, 7 Mesenchymal stem cells (MSC) of bone marrow origin are stromal cells identified by the expression of stage-specific embryonic antigen-1 in mice 8 or GD2 in human, 9 and characterized by their ability to differentiate into multiple lineages. [10] [11] [12] In addition to adult bone marrow, identified sources for isolation of MSC include first trimester fetal blood, 13 liver and bone marrow, fetal lung, 14 chorionic villi of the placenta, 15 and amniotic fluid. 16 MSC can also be isolated at low frequency from umbilical cord blood (UCB) collections. 17, 18 It has been shown that MSC exhibit a powerful immunosuppressive activity, and we have demonstrated that such an effect is primarily the consequence of a non-specific antiproliferative activity, 19, 20 which targets other types of hematopoietic cells as well as cells of non-hematopoietic origin. 21 They have been tested with encouraging results in the treatment of GVHD [22] [23] [24] and with discordant outcomes in autoimmune diseases. [25] [26] [27] The selective activity of MSC on the cell cycle suggests that they could be particularly effective at preventing the expansion of pathogenic T cells rather than inhibiting immune effectors of disease.
To investigate these questions, we have utilized MSC from UCB (UCB-MSC) because, although they appear to exhibit similar progenitor activity of bone marrow-derived MSC, they have the advantage of exhibiting higher self-renewal and proliferative capacities and they can be easily collected without the need of invasive procedures. 17 However, to our knowledge, very little information is available about their ability to mediate an immunosuppressive activity. Therefore, we have tested different modalities of using UCB-MSC for the prophylaxis and treatment of GVHD in a mouse model in which human T cells are injected into non-obese diabetic/severe combined immunodeficiency (NOD/SCID) mice. The results show that the systemic administration of UCB-MSC markedly reduces human T-cell proliferation, the associated tissue damage, and significantly improves the survival of the animals. The effect could be achieved only if UCB-MSC were administered in multiple doses. We conclude that, although UCB-MSC are able to prevent GVHD, they have no effect if administered when the disease has already developed.
Materials and methods

Mice
NOD-LtSz-scid/scid (NOD-SCID) mice between 6 and 10 weeks of age were obtained from Jackson Laboratories (Bar Harbor, ME, USA), bred and maintained in a pathogen-free environment in the BSU at Hammersmith Campus. All procedures were carried out in accordance with the Home Office Animal Act. Mice received 250 cGy of total body irradiation before intravenous injection of 20 Â 10 6 human peripheral blood mononuclear cells (huPBMC) from selected buffy coats, previously labeled with 0.5 mM carboxyfluorescein diacetate succinimidyl ester (CFSE). Where specified, animals also received 3 Â 10 6 UCB-MSC/dose. MSC were obtained from the bone marrow of NOD/SCID recipients by flushing femurs and tibias with medium. Cells were cultivated in six-well plates (Costar, Cambridge, MA, USA) at a concentration of 10 6 /ml nucleated cells in DMEM with high glucose concentration, GLUTAMAX I, 10% fetal calf serum, 100 U/ml penicillin, and 100 mg/ml streptomycin (all reagents from Gibco BRL). Cultures were incubated at 371C in a 5% CO 2 atmosphere. After 72 h, non-adherent cells were removed. When cell cultures were 70-80% confluent, adherent cells were expanded. After 2-3 weeks expansion, cells were analyzed at cytofluorimeter for the expressions of MHC class I, CD45, CD14, CD11c, CD34, CD105, CD106 and CD73. All antibodies were purchased from Pharmingen (Oxford, UK).
Generation of MSC
Cytofluorimetric analysis was performed using FACSCalibur (BD Pharmingen) and analyzed with FlowJo 7.0 software (TreeStar Inc.).
Immunohistological analysis
Murine femurs, spleen, liver, lung, kidney, skin, gut and mesenteric lymph node were removed and fixed for 24 h in 10% neutral-buffered formalin (bone marrow was additionally de-calcified in 10% neutral-buffered formalin and 5% formic acid) and embedded in paraffin. The sections were rehydrated and either stained with hematoxylin and eosin or processed for immunohistochemistry by standard procedures using an antihuCD45 antibody (Pharmingen). Immunostaining was performed using the avidin-biotin-peroxidase complex technique and 3-3 0 -diaminobenzidine as chromogen (Vector Laboratories, Burlingame, CA, USA). The staining was selective for human cells and the antibody did not recognize any murine cells in normal NOD/SCID mice.
Molecular analysis
The pRRLsin.cPPT.hCMV.GFP vector, 28 a gift from Loems Ziegler-Heitbrock, was modified to make it Gateway compatible, recombined using pLenti-DEST technology (InvitrogenNovex, Carlsbad, CA, USA) and produced as described previously.
28 UCB-MSC (5 Â 10 4 ) were incubated in six-well plates for 6 h at 371C with variable volumes of cell-free supernatant, containing identical amounts of vector particles. Seventy-two hours after transduction, cells were fixed with phosphate-buffered saline-1% formaldehyde and enhanced green fluorescent protein (EGFP)-expressing UCB-MSC were analyzed by fluorescence-activated cell sorting (FACS). For homing studies, 3 Â 10 6 expanded UCB-MSC-EGFP þ were injected intravenously into subletally irradiated NOD/SCID mice. Two weeks later, mice were killed and blood, spleen, bone marrow, lungs, liver, kidneys, peritoneal lavage, gut, skin, and thymus were collected for DNA extraction and PCR analysis. Genomic DNA was extracted from mouse tissues using the Easy DNA kit (Invitrogen, Groningen, the Netherlands), and 1 mg of DNA was amplified using the primers: 5 0 -ATG GTG AGC AAG GGC GAG GA-3 0 (EGFP forward) and 5 0 -TTA CTT GTA CAG CTC GTC CA-3 0 (EGFP reverse). The glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene was analyzed as control using the primers: 5 0 -TTA GCA CCC CTG GCC AAG G-3 0 (GAPDH forward) and 5 0 -CTT ACT CCT TGG AGG CCA TG-3 0 (GAPDH reverse). The GAPDH primers were used as a DNA amplification control, as they were designed to recognize GAPDH gene regions shared by mouse and human cells.
T-cell proliferation assay
T-cell proliferation assays were performed in round-bottom, 96-well plates (Costar) in a total volume of 0. 
Results
Human PBMC produce a GVHD-like syndrome in NOD/SCID mice Sublethally irradiated NOD/SCID mice were injected intravenously with CFSE-labeled huPBMC, while control mice were irradiated but did not receive huPBMC. The first signs of clinical GVHD like reduced mobility, ruffled fur, weight loss and hunched posture 29 were observable between 6 and 10 weeks after the injection of huPBMC. Recipient mice showed extensive human T-cell proliferation in their peripheral blood as measured by the analysis of the CFSE profile. The first signs of engraftment were detected at day 14 when three distinct peaks indicative of cell division were visible ( Figure 1A ). The human origin of the cells was confirmed by the co-expression of huCD45 and human MHC class I at cytofluorimetric analysis. From day 14 onwards, the proportion of human cells among the total peripheral blood cell population constantly increased, and virtually all the human cells detected in the recipient mice were T cells as demonstrated by the co-expression of huCD3 ( Figure 1B) .
At killing human cell infiltration was also detected in the spleen (32 The cells were seen proliferating in a diffuse pattern. Sections from lung showed features consistent with GVHD characterized by extensive prominent interstitial fibrosis, infiltration of small lymphoid cells and bronchiolitis obliterans ( Figure 1C) . 
GVHD influences the trafficking of infused UCB-MSC
To evaluate the trafficking of human MSC in recipient mice, UCB-MSC were stably transduced with EGFP-encoding reporter gene lentiviral vector system. The lentiviral vector was generated by a triple transfection of a packaging cell line and used to transduce the target cells at multiplicity of infection (MOI) of 15; 3 days after infection the FACS analysis showed 85% of the cells to express the reporter gene (data not shown). To evaluate the influence of GVHD on UCB-MSC distribution, EGFP-expressing UCB-MSC were injected into sublethally irradiated NOD/SCID mice with or without huPBMC. Animals were killed 2 weeks laterFwhen the priming of GVHD effectors is taking place before their expansionFand tissues analyzed for the presence of the transgene by semi-quantitative PCR. When injected alone, UCB-MSC were found only in the bone marrow of all recipients. However, when the cells were administered together with huPBMC, they were detectable not only in the bone marrow but also in lungs and peritoneal washing of all recipients (Figure 2a) . Bone marrow-derived MSC cultivated from both groups of mice were exclusively of human origin as demonstrated by the expression of human MHC class I molecules, and their antigen profile did not differ from the phenotype of the original UCB-MSC used for the injection (Figure 2b ).
UCB-MSC are effective at preventing but not treating GVHD
The antiproliferative activity of cord blood-derived MSC was confirmed in vitro before they were used in vivo. HuPBMC were stimulated with anti-CD3/CD28 cells expander in the presence of different concentrations of UCB-MSC and tested for their proliferative activity after 3 days. UCB-MSC exhibited a dosedependent antiproliferative effect on target cells with maximal activity at 1:5 ratio (Figure 3 ). T-cell proliferation was not affected when human umbilical vein endothelial cells and human endothelial cells were used as negative control (Figure 3) .
The therapeutic effect of UCB-MSC was assessed using different regimens. In the first series of experiments, mice received a single dose of UCB-MSC at time of huPBMC infusion. Animals receiving UCB-MSC did not behave differently from the controls, as assessed by human T-cell expansion in peripheral blood and course of the disease (Figure 4a) . However, when mice received UCB-MSC not only at time of huPBMC injection but also subsequently at weekly intervals for four administrations (total dose of 12 Â 10 6 cells), we observed a marked decrease in human T-cell expansion (between 40 and 60%) and none of the MSC-treated mice developed GVHD (Figure 4b) . Therefore, our data indicate that multiple doses of UCB-MSC are necessary to prevent the development of GVHD in this model.
Finally, we sought to investigate the therapeutic efficacy of UCB-MSC in this model, by administering the cells when GVHD has already developed. To maximize the effect, we treated the recipient mice with UCB-MSC four times every 3 days for a total dose of 12 Â 10 6 cells. Despite the injections of UCB-MSC, the number of human T cells continued to increase in the peripheral blood of recipient mice. Accordingly, the treatment was ineffective at modifying the course of the disease, which was indistinguishable from control mice (Figure 4c ). These studies demonstrate that, at least in this model, UCB-MSC do not interfere with GVHD once it has been fully established.
Discussion
The potent immunosuppressive properties of MSC have attracted much attention and GVHD is currently the main target of their clinical application. In this study, we have tested the ability of UCB-derived MSC to prevent the development or treat the progression of the disease in a mouse model. Other groups have demonstrated the ability of huPBMC to produce GVHD in immunodeficient mice. 30, 31 We have found that human T cells (CD45 þ /CD3 þ ) consistently expand after infusion into sublethally irradiated NOD/SCID mice ( Figure 1 ) and produce clinical and pathologic signs of GVHD. Proliferating human T cells are detectable in peripheral blood as well as in other tissues, in which it is possible to identify massive infiltrates of T cells especially in those which are the main targets of human GVHD, that is mesenteric lymph node, liver, lung and peritoneal lavage. However, in these experimental conditions, the skin appears to be spared. This might be explained by the lack of a cytokine storm that is usually associated with GVHD after high doses of irradiation, 29 because the low dose utilized in our model as a preparatory regimen 32 was sufficient to favor T-cell engraftment 33 but might have had little effect on cytokine production. Nevertheless, a preferential organ involvement was observed.
Cord blood represents a source not only of hematopoietic stem cells but also of MSC and, despite the lower frequency, the expansion potential is significantly higher than in the bone marrow. 17, 18 We have observed that bone marrow-derived MSC and UCB-MSC also share the same phenotype in terms of pattern of antigens expression (data not shown) as well as the in vitro immunosuppressive properties (Figure 3 ). After injection, cells migrated to the bone marrow of the NOD/SCID mice (Figure 2a) , where they engraft and can be subsequently isolated maintaining the same antigen expression profile (Figure 2b ). When UCB-MSC are injected at the same time of huPBMC, their biodistribution is significantly modified since they can also be found in the lung and peritoneal lavage (Figure 2a) . Our results suggest that tissue injury strongly affects the homing of MSC in vivo and this finding is supported by other reports. In fact, it has been shown that MSC specifically home to focal areas of glomerular damage in a rat model of nephropathy, 34 and their use in rats transplanted with cardiac allografts home to the site of allograft rejection and contribute to graft tissue repair. 35 Clear evidence has been provided that the in vivo administration of MSC is effective at prolonging skin allograft survival 36 and preventing or improving autoimmune diseases in animal models. 25, 37 The data on the efficacy of MSC on GVHD in preclinical settings are less encouraging. Using a MHC mismatched donor-recipient pairs, Sudres et al. 38 recently reported that the infusion of MSC is not sufficient to prevent the development of GVHD. One of the possible explanations is that, despite their supposed immunoprivileged features, donor MSC are rejected. Recent findings suggest that MSC can indeed generate an immune response from the recipient and be rapidly eliminated. 39, 40 In our system, recipient mice are profoundly immunodeficient which can justify the success of the MSC effect. Accordingly, Chung et al. 41 have shown that MSC can prevent GVHD when given to a lethally irradiated recipient mouse. Furthermore, we observed that therapeutic efficacy required multiple doses of UCB-MSC to be infused, while only a single dose was used in the Sudres' study. The failure of a single dose to prevent GVHD support the notion that the in vitro antiproliferative effect of MSC is transient, 21 as also suggested by the in vivo experience in mice 25 and human. 24 Despite their efficacy in the prevention of GVHD, UCB-MSC were not able to reverse the course of the disease if administered when GVHD had developed (Figure 4 ). These data confirm previous observations that the immunosuppressive effect is exerted especially at the level of T-cell proliferation rather than effector function. 19 However, there is still the possibility that this failure could be the consequence of the number of UCB-MSC administered. At the beginning of the experiment, the number of human T cells is much lower than at time of GVHD (from undetectable to 90% of the whole mouse T cells) and it is plausible that, in the presence of a high percentage of proliferating T cells, the number of UCB-MSC infused was too low to exert a significant immunosuppressive effect.
Although very limited, the clinical data so far available are partially in contrast with our findings. In fact, while the failure in detecting any effect on the development of GVHD by MSC administered at time of transplantation could be ascribed to the number of infusions, 22 the clinical experience to treat acute GVHD appears encouraging. 23 The poor efficacy of MSC on active GVHD in our model should be ascribed to an inefficient dose of MSC, whereby the proportion of GVHD effectors at time of MSC infusion constitutes probably the vast majority of recipient T cells. In the clinical condition, only a small percentage of alloreactive T cells can be detected also during active GVHD. 42 Overall, our results support the potential of UCB-derived MSC in the management of GVHD. However, the number of effector cells to be targeted should be carefully considered to enhance the success of the treatment. huPBMC (-'-, n ¼ 5), control animals received 20 Â 10 6 huPBMC and saline solution ( , n ¼ 5). The UCB-MSC treated mice did not behave differently from the controls in terms of human T cells proliferation in peripheral blood monitored by FACS analysis (huCD45 þ cells) and clinical signs of GVHD (wasting) (a). Four doses of 3 Â 10 6 UCB-MSC were administered to NOD/SCID mice bearing huPBMC starting the same day of human cells injection (-'-, n ¼ 5), control animals received 20 Â 10 6 huPBMC and saline solution ( , n ¼ 5). A significant decrease of human cells expansion in the peripheral blood and increase in survival was obtained in UCB-MSC-treated mice if compared with the controls (b). For the therapeutic approach four doses of 3 Â 10 6 UCB-MSC were administered to NOD/SCID mice bearing huPBMC starting five weeks before human cells injection when clinical signs of GVHD were already evident (-'-, n ¼ 5). Control animals received huPBMC and saline solution ( , n ¼ 5) and were then monitored for human T-cell proliferation in peripheral blood and clinical signs of GVHD. No effect in human T-cell proliferation and course of the disease was observed in UCB-MSC-treated mice compared with the controls (c). FACS, fluorescence-activated cell sorting; GVHD, graft-versus-host disease; huPBMC, human peripheral blood mononuclear cells; UCB-MSC, umbilical cord blood-derivedmesenchymal stem cells.
